In the present study, to investigate whether ACE2 activation in the brain could be a novel therapeutic target for depression, we examined the effects of DIZE on the duration of immobile behavior using a behavioral-pharmacological test, and explored some mechanisms of action using biochemical and histological assays. Here, ACE2 is linked to depressive symptom measurement.